Page 5 - 《中国药房》2025年11期
P. 5

CHINA    PHARMACY

                                Volume  36,Number  11,  June  15,2025

                                                  Semimonthly

                                               Table  of  Contents



          Expert consensus on rational medication management of targeted PI3K/Akt/mTOR inhibitors in breast cancer
            ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ Writing Group of Expert
            Consensus on Rational Medication Management of Targeted PI3K/Akt/mTOR Inhibitors in Breast Cancer (1289)
          Formulation and interpretation of the Guidelines for the Pharmacist-managed Clinics Service and Document
            Writing and Usage(Reference)  ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ YANG Lijuan,
            LI Quanzhi,WANG Kejing,YE Xiaofen,WANG Zining,YAN Xuelian,HUANG Liang,LI Juan,ZHEN Jiancun (1301)
          Analysis of the drug inventory and use data from tertiary-level children’s hospitals in Jiangsu province  ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅
            ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ DU Wenwen,XU Wei (1306)
          Improvement effects and mechanism of Xiangsha yiwei tang on gastric mucosal injury in rats with chronic

            atrophic gastritis ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅
            ⋅⋅⋅⋅⋅ XIA Pengfei,JIN Di,LIANG Jin,YU Yi,DU Jinjun,JIN Zhanyong,FANG Jun,YANG Xia,LIU Huiwu (1311)
          Screening of initial processing methods for Ligusticum sinense slice based on differential metabolites  ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅
            ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ HE Yu,DONG Yanjing,QIN Qian,WU Danyang,XU Conglong,ZHANG Shouwen (1317)
          Establishment of quantitative analysis of multi-components by single-marker method for content determination

            of flavonoids and phenolic acids in Perilla frutescens leaves⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅
            ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ LI Danyang,DONG Chao,ZHENG Yunfeng,YAN Hui,ZHANG Li (1323)

          Optimization of particle forming process and quality evaluation of Yindan huoxue tongyu granules⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅
            ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ WANG Dandan,CHEN Xueping,BAI Shuxian,WU Zuomin,DONG Jingyuan,YU Xiaotao (1329)
          Study on the in vivo intestinal absorption and tissue distribution of silybin nanocrystals prepared by two methods
            ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ WANG Mengyan,SUN Ying,HUANG Sirui,REN Yabo,CHANG Jinhua,LIU Xigang (1335)
          Effect and mechanism of Jingangteng capsules in the treatment of non-alcoholic fatty liver disease based on gut
            microbiota and metabolomics ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ CHENG Shiyuan,XIONG Yue,
            ZHANG Dandan,LI Jing,SUN Zhiying,TIAN Jiaying,SHEN Li,SHEN Yue,LIU Dan,WEI Qiong,YE Xiaochuan (1340)
          Study on pharmacokinetic characteristics of ciprofol in pregnant and fetal rats ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅
            ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ CHU Wenhao,QIN Yuanman,ZHANG Tiantian,XU Jiaqi,LI Ying,ZHANG Zhiqing (1348)

          Effects of Portulaca oleracea cream on skin pruritus and barrier function in allergic contact dermatitis mice ⋅⋅⋅⋅⋅
            WANG Xiaoxue,CHEN Xia,PU Xiang,FAN Guanwei,KONG Xiangyan,TANG Ying,WU Nana,LUO Jiangli (1352)

          Pharmacodynamic study of Tianjiang xueshuantong pills in the treatment of coronary heart disease  ⋅⋅⋅ LI Wenjie,
            LI Yingying,BIAN Jiang,LIU Ting,GUAN Yunxuan,ZHANG Xibiao,ZHOU Shiliang,SUN Li,JIANG Xi (1358)
          Pharmacoeconomic evaluation of penpulimab in first-line treatment of advanced squamous non-small-cell lung
            cancer ⋅⋅⋅⋅⋅ HU Dongxue,ZHENG Ying,GAO Qian,HU Shiyuan,WANG Danfeng,YU Fangzhu,DONG Lei (1364)
          Cost-utility analysis of tislelizumab in the treatment of locally advanced or metastatic (non-)squamous NSCLC
            ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ WANG Chunyan,WU Jing,SHEN Lixia (1370)

          Clinical observation of dapagliflozin for stable coronary heart disease combined with heart failure ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅
            ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ DONG Yaohui,HU Gang,WANG Xiaohui (1375)
          Comparison of postoperative efficacy between leuprorelin and mifepristone in the treatment of endometriosis  ⋅⋅⋅
            ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ LIU Lizhen,GUO Lifen,LUO Chunyan,PENG Ruihong (1379)
   1   2   3   4   5   6   7   8   9   10